Significance of the basic fibroblast growth factor in the development of arterial hypertension in type 2 diabetes mellitus patients depending on the presence of undifferentiated connective tissue dysplasia

L.L. Sherstyuk, Ye.Ya. Nikolenko


The article presents the results of study on the concentration of the basic fibroblast growth factor (FGF2) in the blood plasma of patients with diabetes mellitus (DM) type 2, depending on the presence of undifferentiated connective tissue dysplasia (UCTD) and arterial hypertension (AH). The research was carried out in the endocrinology department of the Kharkiv Regional Clinical Hospital. The study included 90 patients aged 35 and 45 years who were treated in 2016–2018 with a diagnosis of type 2 DM, duration of no more than 10 years, including 48 patients with visceral and/or skeletal signs of UCTD, and 20 apparently healthy persons of the same age. It has been found that in apparently healthy subjects, the content of FGF2 was 3.6 [1.9; 9.0] pg/ml, in patients with type 2 DM, it was significantly increased — to 22.1 [16.2; 29.3] pg/ml as compared to controls, and in patients with NDST, it was increased to 30.8 [21.6; 39.9] pg/ml in comparison with those without UCTD. According to the results of the correlation analysis, it was found that in case of type 2 DM, the content of FGF2 increased with age (r = 0.649, p < 0.001) and duration of the disease (r = 0.357, p = 0.02), while in the presence of UCTD in patients with DM type 2, this dependence is absent (r = 0.107 and r = 0.059, respectively, p > 0.05), which is due to the initially increased values of FGF2. A statistically significant correlation was found between the content of FGF2 in patients with DM without and with UCTD (r = 0.413; p = 0.006 and r = 0.564; p = 0.001, respectively), the presence and severity of AH and the presence of diabetic nephropathy. It is concluded that FGF2 plays a significant role in the occurrence of AH in patients with DM type 2, especially in the presence of clinical signs of UCTD. Diabetic nephropathy also plays an important role in the pathogenesis of AH in patients with DM type 2, and FGF2 is also involved in the deve­lopment of diabetic nephropathy. The revealed links between FGF2 and the clinical signs of UCTD suggest that they can be used as predictors of AH in patients with DM type 2.


diabetes mellitus type 2; arterial hypertension; undifferentiated connective tissue dysplasia; basic fibroblast growth factor


Алимова И.Л., Пашинская Н.Б., Плескачевская Т.А. Особенности течения сахарного диабета 1 типа у детей и подростков на фоне дисплазии соединительной ткани // Медицинский вестник Северного Кавказа. — 2016. — 11(2). — С. 272-275.

Губанова М.В., Калашникова Л.А., Добрынина Л.А., Шамтиева К.В., Бердалин А.Б. Маркеры дисплазии соединительной ткани при диссекции магистральных артерий головы и провоцирующие факторы диссекции // Анналы клинической и экспериментальной неврологии. — 2017. — 11(4). — С. 19-28. DOI: 10.18454/ACEN.2017.4.2.

Земцовский Э.В., Малеев Э.Г. Малые аномалии сердца и диспластические фенотипы. — СПб.: Изд-во ИВЭСЭП, 2011. — 60 с.

Мартынова А.И., Нечаева Г.И. Национальные рекомендации Российского научного медицинского общества терапевтов по диагностике, лечению и реабилитации пациентов с дисплазиями соединительной ткани. — М.: ООО «Бионика-Медиа», 2016. — 80 с.

Brewer J.R., Mazot P., Soriano P. Genetic insights into the mechanisms of Fgf signaling // Genes. Dev. — 2016. — 30. — Р. 751-771. doi: 10.1101/gad.277137.115.

Carter E.P., Fearon A.E., Grose R.P. Careless talk costs lives: fibroblast growth factor receptor signaling and the consequences of pathway malfunction // Trends Cell Biol. — 2015. — 25. — Р. 221-233. doi: 10.1016/j.tcb.2014.11.003.

House S.L., Wang J., Castro A.M., Weinheimer C., Kovacs A., Ornitz D.M. Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemia-reperfusion injury // Physiol. Rep. — 2015. — 3. — Р. e12278. doi: 10.14814/phy2.12278.

Kinoshita T., Ishikawa Y., Arita M., Akishima-Fukasawa Y., Fujita K., Inomata N. et al. Antifibrotic response of cardiac fibroblasts in hypertensive hearts through enhanced TIMP-1 expression by basic fibroblast growth factor // Cardiovasc. Pathol. — 2014 Mar-Apr. — 23(2). — Р. 92-100. doi: 10.1016/j.carpath.2013.11.001.

Ornitz D.M., Itoh N. The Fibroblast Growth Factor signaling pathway // Wiley Interdiscip. Rev. Dev. Biol. — 2015 May. — 4(3). — Р. 215-266. doi: 10.1002/wdev.176.

Svystonyuk D.A., Ngu J.M., Mewhort H.E., Lipon B.D., Teng G., Guzzardi D.G. et al. Fibroblast growth factor-2 regulates human cardiac myofibroblast-mediated extracellular matrix remodeling // J. Transl. Med. — 2015. — 13. — 147. doi: 10.1186/s12967-015-0510-4.

Wang Z.G., Wang Y., Huang Y., Lu Q., Zheng L., Hu D. еt al. bFGF regulates autophagy and ubiquitinated protein accumulation induced by myocardial ischemia/reperfusion via the activation of the PI3K/Akt/mTOR pathway // Sci. Rep. — 2015. — 5. — 9287. doi: 10.1038/srep09287.

Copyright (c) 2019 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта